Table 2

In-hospital medication administered for the study patients

CharacteristicsTotal (n=1799)STEMI/new LBBB (n=463)UA/NSTEMI (n=1336)p Value
Medications, n (%)
 Aspirin1773 (98.6)460 (99.4)1313 (98.3)0.095
 Clopidogrel1652 (91.8)454 (98.1)1198 (89.7)<0.0001
 Other antiplatelets15 (0.8)6 (1.3)9 (0.7)0.235
 Dual antiplatelet therapy1640 (91.2)452 (97.6)1188 (88.9)<0.0001
 UFH864 (48.0)230 (49.7)634 (47.5)0.410
 LMWH817 (45.4)197 (42.5)620 (46.4)0.151
 Statin1697 (94.3)441 (95.2)1256 (94.0)0.322
 β-blocker1606 (89.3)421 (90.9)1185 (88.7)0.181
 ACEI/ARB1473 (81.9)403 (87.0)1070 (80.1)0.001
 Nitrates1653 (91.9)417 (90.1)1236 (92.5)0.096
 Oral antiglycaemic agents228 (12.7)36 (7.8)192 (14.4)<0.0001
 PPIs746 (41.5)206 (44.5)540 (40.4)0.125
  • ACEI, ACE inhibitor; ARB, angiotensin receptor blocker; LBBB, left bundle branch block; LMWH, low-molecular-weight heparin; NSTEMI, non-ST-segment elevation myocardial infarction; PPIs, proton-pump inhibitors; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina; UFH, unfractionated heparin.